289891-97-0

Upstream product

• 289891-94-7 2-(allyloxy)-1-fluoro-4-(trifluoromethyl)benzene 
• 289891-95-8 2-allyl-6-fluoro-3-(trifluoromethyl)phenol 

Downstream Products

• 1026821-73-7 4-[4-(7-fluoro-4-trifluoromethyl-benzofuran-2-yl)-4-oxo-butyryl]-benzoic acid methyl ester 
• 1027398-46-4 4-[5-(7-fluoro-4-trifluoromethyl-benzofuran-2-yl)-1H-pyrrol-2-yl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as "BHBA compou

Discovery of novel and potent retinoic acid receptor α agonists: Syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives

In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS- induced B-lymphocyte proliferation and exerted RARα selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.